Screener
Theravance Biopharma TBPH Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $652 | $2,568 |
| Accrued personnel-related expenses | 7,825 | 12,592 |
| Accrued clinical and development expenses | 2,395 | 3,373 |
| Accrued general and administrative expenses | 8,816 | 2,052 |
| Operating lease liabilities | 10,795 | 10,945 |
| Income tax payable | — | 5,287 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's accrued expenses?
- Theravance Biopharma (TBPH) reported accrued expenses of $7.83M in Q2 2026.
- How has Theravance Biopharma's accrued expenses changed year-over-year?
- Theravance Biopharma's accrued expenses increased by 7.8% year-over-year, from $7.26M to $7.83M.
- What is the long-term trend for Theravance Biopharma's accrued expenses?
- Over 5 years (2020 to 2025), Theravance Biopharma's accrued expenses has grown at a -18.6% compound annual growth rate (CAGR), from $35.24M to $12.59M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Theravance Biopharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude